RSS-Feed abonnieren

DOI: 10.1055/a-2631-7439
Financial buy-in does not affect outcomes of endoscopic sleeve gastroplasty: Retrospective cohort
Authors

Abstract
Background and study aims
Endoscopic sleeve gastroplasty (ESG) is an effective treatment for obesity but typically is not covered by insurance. It is not known whether patients with financial investment in their endoscopic procedure are more likely to achieve and/or maintain weight loss as compared with those who have no financial buy-in. We aimed to compare treatment adherence and outcomes between patients paying out-of-pocket (OOP) and those who underwent ESG as part of any clinical trial where costs were covered by a study protocol (no payment; NP).
Patients and methods
Data were collected via retrospective chart review. One hundred sixty-four patients who had an ESG with at least 6 months of follow-up were included. Repeated measures with generalized linear model were used to evaluate weight loss at different time points after ESG and labs values at baseline and 1-year follow-up to assess for comorbidity improvement between cohorts. Compliance was evaluated by comparing exercise adherence rates.
Results
The pattern of weight loss and change in laboratory values was not different over time between the OOP group (n = 139) and NP group (n = 25). Patients lost an average of 14% (12.2–15.9) and 12.9% (9.3–16.5) of total body weight over all time points, respectively, in both groups (6, 12 and 24 months). Treatment adherence also did not differ between the groups.
Conclusions
Having “skin in the game” by paying for ESG OOP does not correlate with better outcomes or treatment adherence, which further supports broad insurance coverage for this procedure.
Publikationsverlauf
Eingereicht: 03. April 2024
Angenommen nach Revision: 04. Juni 2025
Accepted Manuscript online:
10. Juni 2025
Artikel online veröffentlicht:
23. Juli 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/).
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
Lea Sayegh, Karl Akiki, Karim Al Annan, Yara Salameh, Khushboo Gala, Kamal Abi Mosleh, Manpreet Mundi, Omar Ghanem, Barham K. Abu Dayyeh, Andrew C. Storm. Financial buy-in does not affect outcomes of endoscopic sleeve gastroplasty: Retrospective cohort. Endosc Int Open 2025; 13: a26317439.
DOI: 10.1055/a-2631-7439
-
References
- 1
Abu Dayyeh BK,
Rajan E,
Gostout CJ.
Endoscopic sleeve gastroplasty: a potential endoscopic alternative to surgical sleeve
gastrectomy for treatment of obesity. Gastrointest Endosc 2013; 78: 530-535
Reference Ris Wihthout Link
- 2
Abu Dayyeh BK,
Bazerbachi F,
Vargas EJ.
et al.
Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective,
multicentre, randomised trial. Lancet 2022; 400: 441-451
Reference Ris Wihthout Link
- 3
Beran A,
Matar R,
Jaruvongvanich V.
et al.
Comparative effectiveness and safety between endoscopic sleeve gastroplasty and laparoscopic
sleeve gastrectomy: a meta-analysis of 6775 individuals with obesity. Obes Surg 2022;
32: 3504-3512
Reference Ris Wihthout Link
- 4
Levine JA.
Poverty and Obesity in the U.S. Diabetes 2011; 60: 2667-2668
Reference Ris Wihthout Link
- 5
Ard JD,
Emery M,
Cook M.
et al.
Skin in the game: Does paying for obesity treatment out of pocket lead to better outcomes
compared to insurance coverage?. Obesity (Silver Spring) 2017; 25: 993-996
Reference Ris Wihthout Link
- 6
Fehervari M,
Fadel MG,
Alghazawi LOK.
et al.
Medium-term weight loss and remission of comorbidities following endoscopic sleeve
gastroplasty: A systematic review and meta-analysis. Obesity Surg 2023; 33: 3527-3538
Reference Ris Wihthout Link
- 7
Jannah N,
Hild J,
Gallagher C.
et al.
Coverage for obesity prevention and treatment services: analysis of Medicaid and state
employee health insurance programs. Obesity (Silver Spring) 2018; 26: 1834-1840
Reference Ris Wihthout Link
- 8
Baig K,
Dusetzina SB,
Kim DD.
et al.
Medicare Part D coverage of antiobesity medications - Challenges and uncertainty ahead.
N Engl J Med 2023; 388: 961-963
Reference Ris Wihthout Link
- 9
Haseeb M,
Chhatwal J,
Xiao J.
et al.
Semaglutide vs endoscopic sleeve gastroplasty for weight loss. JAMA Network Open 2024;
7: e246221-e
Reference Ris Wihthout Link
- 10
Puhl RM,
Heuer CA.
The stigma of obesity: a review and update. Obesity (Silver Spring) 2009; 17: 941-964
Reference Ris Wihthout Link
- 11
Woolford SJ,
Clark SJ,
Butchart A.
et al.
To pay or not to pay: public perception regarding insurance coverage of obesity treatment.
Obesity (Silver Spring) 2013; 21: E709-E714
Reference Ris Wihthout Link
- 12
Puhl RM,
Brownell KD.
Confronting and coping with weight stigma: an investigation of overweight and obese
adults. Obesity (Silver Spring) 2006; 14: 1802-1815
Reference Ris Wihthout Link
- 13
Mundi MS,
Hurt RT,
Phelan SM.
et al.
Associations between experience of early childhood trauma and impact on obesity status,
health, as well as perceptions of obesity-related health care. Mayo Clin Proc 2021;
96: 408-419
Reference Ris Wihthout Link